Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease

Circulation

Volumn 108, Issue 4, 2003, Pages 395-398

  Nagueh, Sherif F ^a   McFalls, Judy ^b   Meyer, Denise ^b   Hill, Rita ^b   Zoghbi, William A ^b   Tam, James W ^b   Quiñones, Miguel A ^b   Roberts, Robert ^b   Marian, A J ^b  

^a Section of Cardiology   (United States)

^b NONE

Author keywords

Cardiomyopathy; Genetics; Hypertrophy; Screening

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CLINICAL GENETICS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIASTOLE; DISEASE COURSE; FEMALE; FOLLOW UP; GENDER; GENE MUTATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PARAMETER; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PULMONARY VEIN; SYSTOLE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VEIN BLOOD FLOW;

ADOLESCENT; ADULT; BLOOD FLOW VELOCITY; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CARRIER PROTEINS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE DETECTION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; VENTRICULAR MYOSINS;

EID: 0041663643     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000084500.72232.8D     Document Type: Article

References (11)

1. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655-670.
2. Marian AJ, Wu Y, Lim DS, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest. 1999;104:1683-1692.
3. Nagueh SF, Kopelen HA, Lim DS, et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000;102:1346-1350.
4. Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104:128-130.
5. Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992-2997.
6. Cardim N, Perrot A, Ferreira T, et al. Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. Am J Cardiol. 2002;90:128-132.
7. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
8. Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation. 1999;99:254-261.
9. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin 11 blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-791.
10. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104:317-324.
11. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002;109:1013-1020.